论文部分内容阅读
赛诺菲-安万特公司(Sanofi-Aventis)于近期宣布,称其开发的胰高血糖素样肽-1(GLP-1)受体激动剂lixisenatide在一项Ⅲ期临床研究中获得阳性结果。在该项名为GetGoal-S、为期24周、共859名曾
Sanofi-Aventis recently announced that it has produced a positive result for a phase III clinical trial of its developed glucagon-like peptide-1 (GLP-1) receptor agonist, lixisenatide . In the project called GetGoal-S, a total of 859 had 24 weeks